236 related articles for article (PubMed ID: 7964961)
41. Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience.
Sorbe B; Andersson H; Schmidt M; Söderberg M; Högberg T; Wernstedt L; Janson ET; Ehrnström B; Kjaer M; Havsteen H
Support Care Cancer; 1994 Nov; 2(6):393-9. PubMed ID: 7858934
[TBL] [Abstract][Full Text] [Related]
42. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
43. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
[TBL] [Abstract][Full Text] [Related]
44. [Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study].
Nukariya N; Kobayashi K; Ishihara Y; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
Gan To Kagaku Ryoho; 1996 May; 23(6):757-71. PubMed ID: 8645027
[TBL] [Abstract][Full Text] [Related]
45. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
[TBL] [Abstract][Full Text] [Related]
46. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
47. Compassionate use of tropisetron in patients at high risk of severe emesis.
Bleiberg H; Van Belle S; Paridaens R; De Wasch G; Dirix LY; Tjean M
Ann Oncol; 1993; 4 Suppl 3():43-5. PubMed ID: 8364000
[TBL] [Abstract][Full Text] [Related]
48. Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment.
Bleiberg H; Van Belle S; Paridaens R; De Wasch G; Dirix LY; Tjean M
Drugs; 1992; 43 Suppl 3():27-32. PubMed ID: 1380430
[TBL] [Abstract][Full Text] [Related]
49. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children.
Gershanovich M; Kolygin B; Pirgach N
Ann Oncol; 1993; 4 Suppl 3():35-7. PubMed ID: 8363998
[TBL] [Abstract][Full Text] [Related]
50. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
Marty M; Kleisbauer JP; Fournel P; Vergnenegre A; Carles P; Loria-Kanza Y; Simonetta C; de Bruijn KM
Anticancer Drugs; 1995 Feb; 6 Suppl 1():15-21. PubMed ID: 7749165
[TBL] [Abstract][Full Text] [Related]
51. Tropisetron (Navoban) in the control of nausea and vomiting induced by combined cancer chemotherapy in children.
Ozkan A; Yildiz I; Yüksel L; Apak H; Celkan T
Jpn J Clin Oncol; 1999 Feb; 29(2):92-5. PubMed ID: 10089950
[TBL] [Abstract][Full Text] [Related]
52. [Preventive efficacies of china-made tropisetron hydrochloride and Navoban on chemotherapy-induced nausea and vomiting: a randomized controlled clinical trial].
Xie M; Wu HY; Guo Y; Liu JL; Guan ZZ; Liu YL; Wang PH; Chen Q; Huang P; Yang JW
Ai Zheng; 2005 Aug; 24(8):998-1001. PubMed ID: 16086881
[TBL] [Abstract][Full Text] [Related]
53. Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: a pilot study with ACTH-Depot plus tropisetron.
Santini D; Vincenzi B; Fossati C; D'Angelillo RM; Patti G; Bianco V; Avvisati G; Tonini G
Med Oncol; 2001; 18(2):131-5. PubMed ID: 11778758
[TBL] [Abstract][Full Text] [Related]
54. Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
Chang TC; Hsieh F; Lai CH; Tseng CJ; Cheng HH; Li CL; Michael BJ; Soong YK
Cancer Chemother Pharmacol; 1996; 37(3):279-85. PubMed ID: 8529290
[TBL] [Abstract][Full Text] [Related]
55. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy.
Bruntsch U; Rüfenacht E; Parker I; Drechsler S; de Bruijn K
Ann Oncol; 1993; 4 Suppl 3():25-9. PubMed ID: 8363995
[TBL] [Abstract][Full Text] [Related]
56. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
57. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
58. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research.
J Clin Oncol; 1995 Sep; 13(9):2417-26. PubMed ID: 7666102
[TBL] [Abstract][Full Text] [Related]
59. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
[TBL] [Abstract][Full Text] [Related]
60. Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting.
Anderson H; Thatcher N; Howell A; Logan K; Sage T; de Bruijn KM
Eur J Cancer; 1994; 30A(5):610-5. PubMed ID: 8080674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
